Bill Few Associates Inc. Acquires 1,283 Shares of Organon & Co. (NYSE:OGN)

Bill Few Associates Inc. lifted its holdings in Organon & Co. (NYSE:OGN) by 10.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,866 shares of the company’s stock after purchasing an additional 1,283 shares during the quarter. Bill Few Associates Inc.’s holdings in Organon & Co. were worth $207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Prospera Private Wealth LLC purchased a new stake in Organon & Co. in the third quarter worth approximately $25,000. Horizon Bancorp Inc. IN raised its stake in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after buying an additional 1,585 shares during the last quarter. William B. Walkup & Associates Inc. bought a new position in shares of Organon & Co. during the 2nd quarter valued at $31,000. Versant Capital Management Inc boosted its stake in shares of Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after buying an additional 1,324 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares during the period. 77.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $21.33.

Organon & Co. Stock Up 0.0 %

OGN opened at $15.88 on Thursday. The firm’s 50 day simple moving average is $15.32 and its two-hundred day simple moving average is $18.13. The company has a market capitalization of $4.09 billion, a PE ratio of 3.15, a PEG ratio of 0.87 and a beta of 0.76. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same period in the prior year, the business posted $0.78 earnings per share. Organon & Co.’s revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, equities analysts forecast that Organon & Co. will post 3.82 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.05%. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.